NCT03481101 (WHENII) is a NA clinical trial of PET/CT in Non Small Cell Lung Cancer, sponsored by Rigshospitalet, Denmark.

Who is sponsoring NCT03481101?

NCT03481101 is sponsored by Rigshospitalet, Denmark.

What drugs are being tested in NCT03481101?

Interventions in NCT03481101: PET/CT.

What condition does NCT03481101 study?

NCT03481101 studies Non Small Cell Lung Cancer, Circulating Tumor Cell, Circulating Tumor DNA.

Is NCT03481101 still recruiting?

NCT03481101 is currently status unknown. Last updated 8 October 2020.

Last reviewed 2020-10-08 · How we verify

NCT03481101: WHENII

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

WHENII - Early Response Evaluation With FDG-PET/CT and Liquid Biopsy in Patients With NSCLC

Status unknown NA Last updated 8 October 2020

What this trial tests

NA trial testing PET/CT in Non Small Cell Lung Cancer in 60 participants. Status unknown.

Timeline

28 February 2018

Primary endpoint
26 February 2021

28 February 2021

Quick facts

Lead sponsor	Rigshospitalet, Denmark
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	60
Start date	28 February 2018
Primary completion	26 February 2021
Estimated completion	28 February 2021
Sites	2 locations across Denmark

Drugs / interventions tested

PET/CT

Conditions studied

Non Small Cell Lung Cancer — all drugs for Non Small Cell Lung Cancer →
Circulating Tumor Cell — all drugs for Circulating Tumor Cell →
Circulating Tumor DNA — all drugs for Circulating Tumor DNA →

Sponsor

Rigshospitalet, Denmark

Who can join

Eligibility, any sex, with Non Small Cell Lung Cancer or Circulating Tumor Cell. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Response evaluation with FDG-PET and free circulating DNA in patients with inoperable lung cancer of non small cell type during first treatment with chemotherapy or immunotherapy.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Liquid Biopsy to Detect Minimal Residual Disease: Methodology and Impact.
Honoré N, Galot R, van Marcke C, Limaye N, et al · · 2021 · cited 50× · PMID 34771526 · DOI 10.3390/cancers13215364
Soluble biomarkers to predict clinical outcomes in non-small cell lung cancer treated by immune checkpoints inhibitors.
Ancel J, Dormoy V, Raby BN, Dalstein V, et al · · 2023 · cited 24× · PMID 37283751 · DOI 10.3389/fimmu.2023.1171649
Prognostic and Predictive Biomarkers in Non-Small Cell Lung Cancer Patients on Immunotherapy-The Role of Liquid Biopsy in Unraveling the Puzzle.
Augustus E, Zwaenepoel K, Siozopoulou V, Raskin J, et al · · 2021 · cited 21× · PMID 33918147 · DOI 10.3390/cancers13071675
An Immunological Perspective of Circulating Tumor Cells as Diagnostic Biomarkers and Therapeutic Targets.
Dotse E, Lim KH, Wang M, Wijanarko KJ, et al · · 2022 · cited 12× · PMID 35207611 · DOI 10.3390/life12020323

Verify or expand the search:

Other trials of PET/CT

Trials testing the same drug.

NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
NCT07523997 — Imaging of Endometriosis With Total-body PET-CT (PET-Endo) · not yet recruiting
NCT06914427 — PET/CT Imaging Study With Simultaneous Dual-nuclide Imaging Technique · NA · not yet recruiting
NCT06636175 — 64Cu-LLP2A for Imaging Hematologic Malignancies · EARLY_PHASE1 · recruiting
NCT06479187 — PSMAtrack-tracking Changes in PSMA-PET During Initial Therapy for Metastatic Hormone-sensitive Prostate Cancer · Phase 4 · active not recruiting

Other recruiting trials for Non Small Cell Lung Cancer

Currently open trials in the same condition.

NCT06951646 — ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immuno · Phase 2 · recruiting
NCT07503808 — A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types · Phase 1 · recruiting
NCT07269782 — A Phase II Study to Evaluate the Efficacy and Safety of HLX43 + Serplulimab as Neoadjuvant Therapy in Subjects With NSCL · Phase 2 · recruiting
NCT07306624 — Nelmastobart in Combination With Docetaxel in Non Small Cell Lung Cancer · Phase 2 · recruiting
NCT07323732 — A Study of BIO 300 and Thoracic Radiation Therapy in People With Non-Small Cell Lung Cancer and Interstitial Lung Diseas · Phase 2 · recruiting

Other Rigshospitalet, Denmark trials

Trials by the same sponsor.

NCT07401368 — Clinicians' Trust in AI-Based Fetal Growth Estimates · NA · not yet recruiting
NCT07442357 — The Per-procedural Antibiotic Prophylaxis in Patients Undergoing Transcatheter Aortic Valve Implantation Trial · NA · not yet recruiting
NCT07528729 — Alcohol as a Modifiable Risk Factor for Atrial Fibrillation · NA · not yet recruiting
NCT07511439 — Reversible Effects of Oral Contraceptive Removal on Serotonergic Neurotransmission · Phase 4 · not yet recruiting
NCT07467187 — Invasive Home Ventilation in Denmark · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03481101 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Rigshospitalet, Denmark
Last refreshed: 8 October 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03481101.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing